When to start antiretroviral therapy--ready when you are?

The optimal time to start antiretroviral therapy in asymptomatic patients has been one of the central controversies in the care of patients with the human immunodeficiency virus (HIV) since the introduction of the first antiretroviral agent, zidovudine, more than two decades ago.1 Since then, periods of enthusiasm for aggressive early intervention2 have been followed by a more cautious approach.3 This slowly swinging pendulum has been pushed back and forth by the extraordinary benefits of antiretroviral therapy on one side4 and emerging data on its adverse effects on the other.5 The absence of a controlled, prospective study comparing early and deferred . . .

[1]  J. Currier,et al.  Getting smarter--the toxicity of undertreated HIV infection. , 2006, The New England journal of medicine.

[2]  Michael J Silverberg,et al.  Effect of early versus deferred antiretroviral therapy for HIV on survival. , 2009, The New England journal of medicine.

[3]  Douglas D. Richman,et al.  Antiretroviral Treatment of Adult HIV Infection , 2008 .

[4]  Milton C Weinstein,et al.  The survival benefits of AIDS treatment in the United States. , 2006, The Journal of infectious diseases.

[5]  K Henry,et al.  The Case for More Cautious, Patient-Focused Antiretroviral Therapy , 2000, Annals of Internal Medicine.

[6]  J. Gatell,et al.  Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. , 2008, The Journal of infectious diseases.

[7]  Peter Reiss,et al.  Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. , 2008, JAMA.

[8]  G. Friedland.  Early treatment for HIV: the time has come. , 1990, The New England journal of medicine.

[9]  Rodolphe Thiébaut,et al.  Combination antiretroviral therapy and the risk of myocardial infarction , 2003 .

[10]  Amalio Telenti,et al.  Antiretroviral Treatment of Adult HIV Infection2010 Recommendations of the International AIDS Society–USA Panel , 2010 .

[11]  Charles Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[12]  S. Cole,et al.  Accounting for leadtime in cohort studies: evaluating when to initiate HIV therapies , 2004, Statistics in medicine.

[13]  Atlanta,et al.  Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. , 2006, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[14]  D. Ho,et al.  Time to hit HIV, early and hard. , 1995, The New England journal of medicine.

[15]  W. K. Henry,et al.  CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection , 2008, AIDS.

[16]  Jonathan AC Sterne,et al.  Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies , 2002, The Lancet.